Mechanisms of dendritic cell-based vaccination against infection

Fajardo-Moser, Marcela; Berzel, Simon; Moll, Heidrun

doi:10.1016/j.ijmm.2007.07.003

Cited by 48 publications

(24 citation statements)

References 103 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, while a polarized Th1 cytokine profile is linked to protection in LCand CpG/mDC-immunized mice, no strong correlation (or specific roles for IL-12 and IFN-␣) is observed in the case of pDC-immunized mice (24). These findings indicate the functional diversity of DC subsets in the control of L. major infection and the importance of mounting adequate local immune responses to control the infection (63). However, direct lesional injection of L. amazonensis Ag-pulsed mDCs (10 6 cells per mouse) together with rIL-12 failed to promote healing in mice chronically infected with L. amazonensis (35).…”

Section: Dc-based Immunotherapy In Murine Models Of Leishmaniasismentioning

confidence: 85%

Modulation of Dendritic Cell Function by Leishmania Parasites

Soong

2008

The Journal of Immunology

View full text Add to dashboard Cite

The interactions between Leishmania parasites and dendritic cells (DCs) are complex and involve paradoxical functions that can stimulate or halt T cell responses, leading to the control of infection or progression of disease. The magnitude and profile of DC activation vary greatly, depending upon the Leishmania species/strains, developmental stages, DC subsets, serum opsonization, and exogenous DC stimuli involved in the study. In general, the uptake of Leishmania parasites alone can trigger relatively weak and transient DC activation; however, the intracellular parasites (amastigotes) are capable of down-modulating LPS/IFN-γ-stimulated DC activation via multiple mechanisms. This review will highlight current data regarding the initial interaction of DC subsets with invading parasites, the alterations of DC signaling pathways and function by amastigotes, and the impact of DC functions on protective immunity and disease pathogenesis. Available information provides insight into the mechanisms by which DCs discriminate between the types of pathogens and regulate appropriate immune responses.

show abstract

Section: Dc-based Immunotherapy In Murine Models Of Leishmaniasismentioning

confidence: 85%

Modulation of Dendritic Cell Function by Leishmania Parasites

Soong

2008

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…[38][39][40] We therefore reasoned that the duration of GM-CSF stimulation might be a critical variable.…”

Section: Discussionmentioning

confidence: 99%

Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice

Wang

Dong²,

Xiao

et al. 2015

Cell Mol Immunol

View full text Add to dashboard Cite

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is known to be a potential vaccine adjuvant despite contradictory results from animal and human studies. The discrepancies may be due to the different doses and regimens of GM-CSF that were used, given that either mature or immature dendritic cells (DCs) could be induced under different conditions. To test the hypothesis that GM-CSF can be used as a novel adjuvant for a hepatitis B virus (HBV) therapeutic vaccine, we administered GM-CSF once per day for three days prior to vaccination with recombinant HBV vaccine (rHBVvac) in mice. We observed greater DC maturation in these pre-treated animals at day 3 as compared to day 1 or day 2 of daily GM-CSF administration. This strategy was further investigated for its ability to break the immune tolerance established in hepatitis B surface antigen-transgenic (HBsAg-Tg) animals. We found that the levels of induced anti-HBsAg antibodies were significantly higher in animals following three days of GM-CSF pre-treatment before rHBV vaccination after the third immunization. In addition to the increase in anti-HBsAg antibody levels, cell-mediated anti-HBsAg responses, including delayed-type hypersensitivity, T-cell proliferation, interferon-c production, and cytotoxic T lymphocytes, were dramatically enhanced in the three-day GM-CSF pre-treated group. After adoptive transfers of CD8 1 T cells from immunized animals, antigen-specific CD8 1 T cells were observed in the livers of recipient HBsAg-Tg animals. Moreover, the three-day pre-treatments with GM-CSF prior to rHBVvac vaccination could significantly eliminate HBsAg-positive hepatocytes, suggesting beneficial therapeutic effects. Therefore, this protocol utilizing GM-CSF as an adjuvant in combination with the rHBVvac vaccine has the potential to become a novel immunotherapy for chronic hepatitis B patients. Cellular & Molecular Immunology

show abstract

“…Hence, DCs have caught the attention for their use as therapeutic agents for immunotherapy of cancer 6 and infectious diseases, such as human immunodeficiency virus (HIV). 7,8 Research on DC-based immunotherapy is currently focusing on the vaccine-mediating effects on the adaptive immune system, aiming at inducing (tumor)antigen-specific cytotoxic T lymphocytes (CTLs). Less extensively studied is the effect of DC-based immunotherapy on gd T cells.…”

Section: Introductionmentioning

confidence: 99%

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy

Anguille

et al. 2015

OncoImmunology

View full text Add to dashboard Cite

These authors equally contributed to the work.Keywords: gd T cell, cancer, DC-mediated gd T cell activation, dendritic cell, immunotherapy Abbreviations: gd, gamma delta; BCG, Bacillus Calmette-Guerin; BrHPP, bromohydrin pyrophosphate; CTL, cytotoxic T lymphocyte; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; HIV, human immunodeficiency virus; HMBPP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; iDC, immature DC; IFN, interferon; IL, interleukin; IPP, isopentyl pyrophosphate; mDC, myeloid dendritic cell; MHC, major histocompatibility complex; mo-DC, monocyte-derived dendritic cell; pDC, plasmacytoid dendritic cell; PD, programmed cell death protein; TCR, T-cell receptor; Th, T-helper cell; TLR, toll-like receptor; TNF, tumor necrosis factor; Treg, regulatory T cellGamma delta (gd) T cells are the all-rounders of our immune-system with their major histocompatibility complexunrestricted cytotoxicity, capacity to secrete immunostimulatory cytokines and ability to promote the generation of tumor antigen-specific CD8 C and CD4 C T cell responses. Dendritic cell (DC)-based vaccine therapy has the prospective to harness these unique features of the gd T cells in the fight against cancer. In this review, we will discuss our current knowledge on DC-mediated gd T cell activation and related opportunities for tumor immunologists.

show abstract

Mechanisms of dendritic cell-based vaccination against infection

Cited by 48 publications

References 103 publications

Modulation of Dendritic Cell Function by Leishmania Parasites

Modulation of Dendritic Cell Function by Leishmania Parasites

Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy

Contact Info

Product

Resources

About